Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-06-26
2007-06-26
Kemmerer, Elizabeth (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S143100, C514S015800
Reexamination Certificate
active
10123036
ABSTRACT:
The present invention relates to the prevention and treatment of injury and diseases to the liver, biliary tract, bile ducts, gall bladder and related hepatobiliary system. Specifically, the present invention relates to methods for decreasing the action of the RON receptor tyrosine kinase in liver physiology. More specifically, the present invention relates to the use of analogs and antagonists and antibodies for inhibiting the action of the RON receptor tyrosine kinase for the prevention and treatment of liver injury or damage in acute and chronic clinical conditions.
REFERENCES:
patent: 4954526 (1990-09-01), Keefer
patent: 5219991 (1993-06-01), Leonard et al.
patent: 5278192 (1994-01-01), Fung et al.
patent: 5315000 (1994-05-01), Degen
patent: 5378725 (1995-01-01), Bonjouklian et al.
patent: 5480906 (1996-01-01), Creemer et al.
patent: 5504103 (1996-04-01), Bonjouklian et al.
patent: 5527685 (1996-06-01), Leonard et al.
patent: 5606029 (1997-02-01), Degen
patent: 5696086 (1997-12-01), Avraham et al.
patent: 5814308 (1998-09-01), Zhang
patent: 5874306 (1999-02-01), Beattie et al.
patent: 5916770 (1999-06-01), Yoshikawa et al.
patent: 5948892 (1999-09-01), Wahl
patent: 6030949 (2000-02-01), Comoglio et al.
patent: 6245754 (2001-06-01), Kozikowski et al.
patent: 6248560 (2001-06-01), Wahl
patent: 2003/0212256 (2003-11-01), Edinger et al.
patent: WO 98/55141 (1998-06-01), None
Wang et al. Regulation of the RON Receptor Tyrosine Kinase Expression in Macrophages: Blocking the RON Gene Transcription by Endotoxin-In duced Nitric Oxide. Journal of Immunology, 2000 vol. 164:3815-3821.
Leonard et al. Macrophage Stimulating Protein. Advances in Cancer Research, 2000 vol. 77:139-167.
Branch, A. A Good Antisense is Hard to Find. TIBS, Feb. 1998 vol. 23, pp. 45-50.
Crystal, RG. Transfer of Genes to Humans: Early Lessons and Obstacles to Success. Science, 1995 vol. 270:404-410.
Anderson, WF. Human Gene Therapy. Nature, 1998 vol. 392 (6679 Suppl):25-30.
Verma et al. Gene Therapy—Promises, problems and prospects. Nature, 1997 vol. 389:239-242.
Rudinger J in Peptide Hormones. Editor Parsons JA. pp. 1-7, 1976, University Park Press, Baltimore.
Bowie et al., 1990. Science, vol. 247, pp. 1306-1310. Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions.
Ngo et al., 1994. Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox. The Protein Folding Problem and Tertiary Structure Prediction.
Cirrhosis of the Liver. National Digestive Diseases Information Clearinghouse (NIDDIC website: digestive.niddk.nih.gove/ddiseases/pubs/cirrhosis; accessed May 30, 2006; 7 pages.
Definition of Hepatobiliary. MedicineNet.com; medterms.com; accessed May 30, 2006; 1 page.
Feng et al., Science in China Series C Life Sciences; 1999, 42; 5: 548-553.
Bezerra et al, Are Hepatocyte Growth Factor-like Protein and Macrophage Stimulating Protein the Same Protein?. 1999Protein Science2, 666-668.
Chen, Y.-Q. et al, Activation of the RON Receptor Tyrosine kinase Inhibits Inducible Nitric Oxide Synthase (iNOS) Expression by Murine Peritoneal Exudate Macrophages: Phosphatidylinositol-3 Kinase is Required for RON-Mediated Inhibition of iNOS Expression,. 1998J. Immunol. 161:4950-4959.
Correll, P. H. et al., Dergulated Inflammatory Response in Mice Lacking the STK/RON Receptor Tyrosine Kinase, 1997Genes Funct. 1:69-83.
Follenzi, A., et al., Cross-talk Between the Proto-Oncogenes Met and Ron, 2000Oncogene19:3041-3049.
Gaudino, G., et al., The Prot-oncogene RON is Involved in Development of Epithelial, Bone and Neuro-endocrine Tissues, 1995Oncogene11:2627.
Han et al., Characterization of the DNF15S2 Locus on Human Chromosome 3: Identification of a Gene Coding for Four Kringle Domains with Homology to Hepatocyte Growth Factor, 1991Biochemistry30, 9768-9780.
Leonard, E. J. and Danilkovitch, A., Macrophage Stimulating Protein, 2000Adv. Cancer Res. 77:139-167.
McDowell, S. A., et al., The Role of the Receptor Tyrosine Kinase Ron in Nickel-Induced Acute Lung Injury, 2002Am. J. Respir. Cell Mol. Biol. 26:99-104.
Mera, A. et al., Induction of Cell Shape Changes Through Activation of the Interleukin-3 Common β Chain Receptor by the RON Receptor-type Tyrosine Kinase, 1999J. Biol. Chem. 274:15766-15774.
Muraoka, R. S. et al., the Ron/STK Receptor Tyrosine Kinase is Essential for Peri-implantation Development in the Mouse, 1999J. Clin. Invest. 103:1277-1285.
Persons, D. A., et al., Fv2 Encodes a Truncated Form of the Stk Receptor Tyrosine Kinase, 1999Nat. Genet. 23:159-165.
Ronsin, C. et al., A Novel Putative Receptor Protein Tyrosine Kinase of the MET Family, 1993Oncogene5: 1195-1202.
Saavedra, J. E., et al., Targeting Nitric Oxide (NO) Delivery in Vivo. Design of a Liver-Selective NO Donor Prodrug that Blocks Tumor Necrosis Factor-a-Induced Apoptosis and Toxicity in the Liver, 1997,J. Med. Chem. 40:1947-1954.
Torok, N. J. et al., Nitric Oxide Inhibits Apoptosis Downstream of Cyrochrome C Release, 2000Hepatology32:332A.
Wang, M.-H., et al., Macrophage-stimulating Protein Inhibits Induction of Nitric Oxide Production by Endotoxin- or Cytokine-stimulated Mouse Macrophages, 1994J. Biol. Chem. 269:14027.
Wang, M.-H., et al., Requirement of Phosphatidylinositol-3 Kinase of Epithelial Cell Migration Activated by Human Macrophage Stimulating Protein, 1996Oncogene13, 2167-2175.
Wang, Ming-Hai, et al.,Macrophage Stimulating Protein(MSP)Binds to Its Receptor via the MSP β Chain, Journal of Biological Chemistry, 272:27, pp. 16999-17004 (1997).
Waltz, Susan, et al.,Functional Characterization of Domains contained in Hepatocyte Growth Factor-like Protein, Journal of Biological Chemistry, 272:48, pp. 30526-30537 (1997).
Waltz, Susan, et al.,Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses, Journal of Clin. Investigation 108:4, pp. 567-576 (Aug. 2001).
Kaplowitz, Neil; “Hepatology Highlights,”Liver Biology Biology and Pathology Editor, pp. 1037-1038.
Leonis, Mike A.; Toney-Early, Kenya; Degen, Sandra J. F.; and Waltz, Susan E.; Deletion of the Ron Receptior Tyrosine Kinase Domain in Mice Provides Protection From Endotoxin-Induced Acute Liver Failure,HEPATOLOGY, Nov. 2002: 1053-1060.
Rao, R.K.; Seth, A; and Sheth, P.; “Recent Advances in Alcoholic Liver Disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease,”American Journal of Physiology—Gastrointestinal and Liver Physiology, 286: G881-G884, © 2004; (information current as of Apr. 27, 2005).
Degen Sandra J.
Leonis Mike A.
Waltz Susan E.
Borgeest Christina
Children's Hospital Medical Center
Frost Brown Todd LLC
Kemmerer Elizabeth
LandOfFree
Methods for the treatment of hepatic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of hepatic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of hepatic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3848211